PALO ALTO, Calif.--(BUSINESS WIRE)--Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced today that Elizabeth Iorns, Ph.D., CEO of Science Exchange, has been elected to serve her first term on the Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT) beginning November 1, 2017. Members of DCAT’s Board of Directors are charged with the important work of guiding the organization’s strategic initiatives and activities.
"We are delighted to have Dr. Iorns join the Board of Directors,” said DCAT Executive Director Margaret Timony. “She brings a unique mix of leadership experiences that will add a valuable perspective to the board.”
“I am honored to join the board and work together with this great team to address key initiatives related to the pharmaceutical industry,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Our mission at Science Exchange is to help accelerate innovation and scientific discoveries, and as a scientist myself, I feel joining DCAT’s board is a perfect opportunity for me to share my ideas and insights to support and advance its programs and services.”
About DCAT
The Drug,
Chemical & Associated Technologies Association (DCAT) is a
not-for-profit, global business development association whose unique
membership model integrates both innovator and generic drug
manufacturers and suppliers of ingredients, development and
manufacturing services, and related technologies. We are committed to
provide programs, events and services that help our members meet their
business objectives, expand their network of customers and suppliers,
and gain insight into industry trends, markets, and those issues
impacting pharmaceutical development and manufacturing.
About Science Exchange
Science Exchange is the world's
leading and most secure platform for outsourced research, providing an
efficient procure-to-pay platform for ordering 6,000+ services from a
network of more than 2,500 qualified scientific service providers, all
with pre-established contracts in place that protect client intellectual
property and confidentiality. The platform increases access to
innovation and improves productivity, freeing scientists from
administrative tasks and delays associated with sourcing, establishing
and managing service provider contracts. Additionally, the Science
Exchange enterprise program enables large R&D organizations to
consolidate research outsourcing spend into a single strategic
relationship, driving efficiency, improving transparency and oversight,
and delivering cost savings. Since being founded in 2011, Science
Exchange has raised more than $58 million from Norwest Venture Partners,
Maverick Capital Ventures, Union Square Ventures, Collaborative Fund,
Index Ventures, OATV, the YC Continuity Fund, and others. For more
information, visit www.ScienceExchange.com.
Follow the company on Twitter @ScienceExchange.
